Clinical & Cellular Immunology Review Shows Company Can Break Ad5 Immunity Tolerance
SEATTLE (December 21, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop both immunotherapeutics and preventive vaccines, announced today that novel data from numerous preclinical studies of its Ad5 platform was published in the Journal of Clinical & Cellular Immunology’s special issue on Vaccine Development and Immune Response in a review entitled, “New Recombinant Ad5 Vector Overcomes Ad5 Immunity Allowing for Multiple Safe, Homologous Immunizations.”
Recombinant viral vectors have been utilized in gene therapy, vaccination, and immunotherapy, but have encountered clinical challenges as they are recognized as foreign entities to the host and cleared from the body before having a clinical effect. Etubics has reported on a new viral vector technology, Etubics Platform (Ad5[E1-, E2b-]), that can induce an immune response even in the presence of vector immunity. Etubics has reported immunization and immunotherapy results in pre-clinical trials in mice, ferrets and monkeys for CEA and HER2/neu expressing cancers as well as HIV/SIV and H1N1 influenza.
Etubics has overcome the issue of Ad5 immunity through reducing the expression of the viral vector proteins by removing extensive genetic regions of the gene delivery viral backbone. Reduced expression of Ad5 viral genes in a recombinant vector platform is advantageous in vaccine development because: it reduces antigenic competition between the target and Ad5 proteins; provides greater longevity of target transgene expression creating a larger immunologic stimulus; and decreases adverse effects, allowing for higher and more frequent doses of vaccine.
Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics stated, “Adenovirus vectors have shown to be advantageous, yet the challenge was overcoming the immunity against the immunizing agent that soon followed. By breaking through Ad5 immunity, Etubics can create products that are effective in driving cell mediated immunity and antibody in all patients.”
Etubics pre-clinical work has been funded through grants from the National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI). To view the review online, visit http://www.omicsonline.org/2155-9899/2155-9899-S4-001.pdf.
Etubics is developing the next generation in vaccines and immunotherapies, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. Etubics has completed a Phase I/IIa clinical trial with an immunotherapeutic product candidate to treat colorectal cancer. Etubics Phase I/IIa colorectal cancer trial has been funded primarily through grants from the National Cancer Institute (NCI). The NCI also awarded earlier grants to Etubics for its colorectal and breast cancer pre-clinical and colorectal clinical work.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 firstname.lastname@example.org